Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

Rhea-AI Summary

BioXcel Therapeutics (BTAI) is sponsoring a virtual roundtable on Dec. 8, 2025 at 10:00 a.m. EST focused on treating acute agitation linked to bipolar disorder and schizophrenia.

Hosted by journalist Anjalee Khemlani, the one-hour event features Drs. Leslie Citrome, Marc Milano, and Leon Ravin discussing the potential for safe, self‑administered at‑home treatments and shifting care outside emergency and inpatient settings. The release cites an estimated 57–77 million annual at‑home agitation episodes in the U.S. Pre-registration is available and a recording will be posted to the BioXcel Therapeutics website.

Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8

Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home

NEW HAVEN, Conn., Dec. 03, 2025 (GLOBE NEWSWIRE) -- As millions of patients and caregivers continue to struggle with acute agitation episodes associated with bipolar disorder and schizophrenia, a timely and highly anticipated virtual roundtable will bring together leading medical experts to discuss the future of care, including the growing potential for safe, effective self-administered treatments at home.

Hosted by Anjalee Khemlani, an award-winning healthcare journalist known for her in-depth reporting at Yahoo Finance and NJBIZ, the one-hour event will take place Monday, Dec. 8, at 10 a.m. EST. Pre-registration is now open at the following link: https://event.webcasts.com/starthere.jsp?ei=1744467&tp_key=14d071615e.

With an estimated 57 to 77 million episodes of agitation associated with bipolar disorders and schizophrenia in the at-home setting occurring annually in the U.S., this roundtable aims to give clinicians, caregivers, investors, and healthcare professionals an inside look at how treatment paradigms are shifting, and what innovations may soon redefine patient care outside emergency rooms, psychiatric facilities, and skilled nursing settings.

The roundtable participants are:

• Leslie Citrome, M.D., M.P.H., Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College
  

• Marc A. Milano, M.D., FACEP, Chair, Department of Emergency Medicine at Newark Beth Israel Medical Center and Children’s Hospital of New Jersey
  

• Leon Ravin, M.D., Psychiatrist and Statewide Psychiatric Medical Director for the Division of Public and Behavioral Health, State of Nevada
  

Attendees may ask questions via written Q&A. A recording of the event will be posted to the BioXcel Therapeutics website and available here.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company built on artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.

Contact Information:

Corporate/Investors
Russo Partners
Nic Johnson
nic.johnson@russopartnersllc.com
1.303.482.6405

Media
Russo Partners
David Schull
david.schull@russopartnersllc.com
1.858.717.2310

Source: BioXcel Therapeutics, Inc.

FAQ

When is the BioXcel Therapeutics (BTAI) virtual roundtable on acute agitation?

The event is scheduled for Monday, Dec. 8, 2025 at 10:00 a.m. EST.

Who is hosting the BioXcel (BTAI) virtual roundtable on Dec. 8, 2025?

The session is hosted by award‑winning journalist Anjalee Khemlani.

Which medical experts will speak at the BTAI roundtable on treating acute agitation?

Speakers are Leslie Citrome, M.D., Marc A. Milano, M.D., and Leon Ravin, M.D.

What topics will the BioXcel (BTAI) roundtable cover about at‑home agitation care?

The panel will discuss the opportunities and advantages of self‑administered treatments at home and changes in care pathways outside ERs and inpatient settings.

How many at‑home agitation episodes does the BTAI announcement reference?

The announcement cites an estimated 57 to 77 million at‑home agitation episodes annually in the U.S.

How can investors and clinicians access the BTAI roundtable or recording?

Pre‑registration is available via the event link and a recording will be posted to the BioXcel Therapeutics website after the event.